Living with HER2-negative disease

Stories from people navigating HER2-negative disease — diagnosis, treatment, caregiving, and the ordinary days in between.

1 story

Breast cancer pathology slide beside a molecular test report indicating PIK3CA wild-type status.

Oncology

Gedatolisib Approved for PIK3CA-Wild-Type Breast Cancer

The FDA approved gedatolisib plus fulvestrant, with or without palbociclib, after endocrine therapy progression in PIK3CA-wild-type HR-positive, HER2-negative advanced breast cancer.

Rayan Salih · September 3, 2026 · 6 min

Other conditions

ADHD
Allergy
ALS
Alzheimer's Disease
Antimicrobial Resistance
Anxiety
Asthma
Atopic Dermatitis
Atrial Fibrillation
Autism
Breast Cancer
Cervical Cancer

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.